RFID spending for pharma to grow 34% annually through 2015, GBI Research says
Biggest barriers to RFID adoption include cost and uncertainty of ROI
New research by business intelligence firm GBI Research (New York) estimates that Radio Frequency Identification (RFID) spending for pharma supply chain will grow 34% annually through 2015. In 2008, the industry was valued at $112 million; by 2015, it’s expected to grow to $884 million.
The growth, GBI says, will be fueled by mandates for e-pedigree implementation—in particular, retailer requirements and a California Board of Pharmacy e-pedigree initiative that was postponed in late 2008 but is expected to require implementation in 2015.
The report also found that current market share is 60% hardware, such as tags, readers and label printers, and 40% software and services, including installation, integration, training, maintenance and IT support.
The report, “Radio Frequency Identification (RFID) in Pharmaceuticals—Supply Chain Security Concerns Provide Impetus for RFID Adoption,” offers analysis on the barriers to RFID adoption, namely its prohibitive cost and a lack of information on ROI.
“There are currently only a few services to accurately estimate the return on investment that RFID can offer,” GBI says. “The uncertainty about ROI and the necessity of high cost implementation prevents companies and supply chain participants from adopting RFID solutions.”
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
